The Committee for Orphan Medicinal Products (COMP) is responsible for reviewing applications from persons or companies seeking 'orphan medicinal product designation' for products they intend to develop for the diagnosis, prevention or treatment of life-threatening or very serious conditions that affect not more than 5 in 10,000 persons in the European Union.
The COMP is also responsible for advising the European Commission on the establishment and development of a policy on orphan medicinal products in the EU, and assists the Commission in drawing up detailed guidelines and liaising internationally on matters relating to orphan medicinal products.
COMP members are nominated by the Member States, and are chosen on the strength of their qualifications and expertise with regard to the evaluation of medicinal products. They serve on the committee for a renewable period of three years.
The COMP is composed of:
- a chair, elected by serving COMP members;
- one member nominated by each of the 28 Member States;
- three members nominated by the European Commission to represent patients' organisations;
- three members nominated by the European Commission on the Agency's recommendation;
- one member nominated by Iceland and one by Norway.
See COMP members for the list of current members.
The 'COMP rules of procedure' provide full details of the COMP's responsibilities, composition and the roles of its members.
How useful is this page?
Average rating:Based on 29 ratings
Add your rating:
- See all ratings
19 ratings1 ratings1 ratings6 ratings2 ratings
- Committee for Orphan Medicinal Products (COMP) work plan 2016 (28/01/2016)
- Committee for Orphan Medicinal Products (COMP) work plan 2015 (22/05/2015)
- Policy on scientific publication and representation for European Medicines Agency scientific committees and their members (21/12/2010)
- Policy 9: Appropriate coordination between the Agency's scientific committees (31/10/2008)
European Medicines Agency
30 Churchill Place
London E14 5EU